Hematology

DELAYED platelet engraftment (PE) post-autologous stem cell transplantation (ASCT) in patients with non-Hodgkin lymphoma (NHL) can lead to severe outcomes…

HEALTHCARE professionals are lacking guidance with regard to treating myelofibrosis (MF) with secondary portal hypertension (PHT) or pulmonary hypertension (PH)…

AUTOLOGOUS haematopoietic stem cell transplantation (ASCT) can improve the quality of life (QoL) of patients with multiple sclerosis (MS)…

Researchers have found no significant differences in the effectiveness of immune tolerance induction therapy across different racial and ethnic groups in individuals living with haemophilia A.

Providing opioid prescriptions to children who have experienced pain due to sickle cell disease does not lead to harmful patterns of opioid use. Read more.

A novel classification model for multiple myeloma may provide personalised predictions of treatment outcomes for individual patients. This research has the potential to significantly improve current management of MM.

A new retrospective study from St. Jude Children’s Research Hospital, Memphis, Tennessee, USA, reports treatment delays in young patients with acute lymphoblastic leukaemia (ALL) following COVID-19 diagnosis.

Researchers found that real-world outcomes for individuals who received the standard treatment regimens for multiple myeloma were significantly poorer than outcomes reported in clinical trials.